Sapitinib

DB12183InvestigationalSmall molecule

Sapitinib has been used in trials studying the treatment and basic science of Neoplasms, Breast Cancer, Breast Neoplasms, Metastatic Cancer, and Metastatic Breast Cancer, among others.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2, Epidermal growth factor receptor, and Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Formula / weight: C₂₃H₂₅ClFN₅O₃ · 473.93 g/mol (avg)
Code names: AZD-8931

Resolves to

Compound

UNII3499328002CAS848942-61-0ChEMBLCHEMBL2408045ChEBI132986PubChem11488320

Structure

InChIKeyDFJSJLGUIXFDJP-UHFFFAOYSA-NSMILESCNC(=O)CN1CCC(CC1)OC1=C(OC)C=C2N=CN=C(NC3=CC=CC(Cl)=C3F)C2=C1

Targets

P04626ERBB2P00533EGFRP21860ERBB3

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sapitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account